AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 15760638 — intervention group
Group type: COMPARATOR
Intervention: Controls
Number of subjects: 0
Study 11849382 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol/day) during the luteal phase
Number of subjects: 35
Study 11849382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (40 mmol/day) during the follicular phase
Number of subjects: 35
Study 11849382 — intervention group
Group type: EXPERIMENTAL
Intervention: High sodium diet (250 mmol/day) during the follicular phase
Number of subjects: 35
Study 11849382 — intervention group
Group type: EXPERIMENTAL
Intervention: Low sodium diet (40 mmol/day) during the luteal phase
Number of subjects: 35
Study 10188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber intake
Number of subjects: 12763
Study 10188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin B6 intake
Number of subjects: 12763
Study 10188715 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-tocopherol intake
Number of subjects: 12763
Study 10188715 — intervention group
Group type: COMPARATOR
Intervention: Plant foods and related sub-groups
Number of subjects: 12763
Study 7818125 — intervention group
Group type: EXPERIMENTAL
Intervention: Atracurium 450 micrograms/kg
Number of subjects: 10
Study 7818125 — intervention group
Group type: EXPERIMENTAL
Intervention: Vecuronium 80 micrograms/kg
Number of subjects: 10
Study 7818125 — intervention group
Group type: EXPERIMENTAL
Intervention: Mivacurium 160 micrograms/kg
Number of subjects: 10
Study 30379683 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium DM/NR features
Number of subjects: 54
Study 30379683 — intervention group
Group type: EXPERIMENTAL
Intervention: Premium HAs
Number of subjects: 54
Study 30379683 — intervention group
Group type: COMPARATOR
Intervention: DM/NR features
Number of subjects: 54
Study 30379683 — intervention group
Group type: COMPARATOR
Intervention: Basic DM/NR features
Number of subjects: 54
Study 28923039 — intervention group
Group type: EXPERIMENTAL
Intervention: Calmagen® cream or lotion
Number of subjects: 28
Study 28923039 — intervention group
Group type: COMPARATOR
Intervention: Placebo (inert topical preparation)
Number of subjects: 28
Study 25809680 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-kcal macronutrient and fiber-matched (MF) beef protein (24-g)
Number of subjects: 21
Study 25809680 — intervention group
Group type: EXPERIMENTAL
Intervention: 400-kcal serving size-matched (SS) beef protein (24-g)
Number of subjects: 21
Study 25809680 — intervention group
Group type: COMPARATOR
Intervention: 400-kcal macronutrient and fiber-matched (MF) soy protein (24-g)
Number of subjects: 21
Study 25809680 — intervention group
Group type: COMPARATOR
Intervention: 400-kcal serving size-matched (SS) soy protein (14-g)
Number of subjects: 21
Study 23716559 — intervention group
Group type: EXPERIMENTAL
Intervention: Bortezomib-dexamethasone
Number of subjects: 163
Study 21316088 — intervention group
Group type: EXPERIMENTAL
Intervention: Tadalafil 20 mg
Number of subjects: 50
Study 21316088 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17653957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625/2.5 mg CE/MPA for 6 months
Number of subjects: 1028
Study 17653957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45/1.5 mg CE/MPA for 6 months
Number of subjects: 1028
Study 17653957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3/1.5 mg CE/MPA for 6 months
Number of subjects: 1028
Study 17653957 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625/2.5 mg CE/MPA
Number of subjects: 1028
Study 16403987 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin C (200 mg/day) plus Aspirin (300 mg/day)
Number of subjects: 0
Study 16403987 — intervention group
Group type: COMPARATOR
Intervention: Aspirin (300 mg/day)
Number of subjects: 0
Study 11812877 — intervention group
Group type: COMPARATOR
Intervention: Calcium carbonate (3 g/day)
Number of subjects: 45
Study 11812877 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferric citrate (3 g/day)
Number of subjects: 45
Study 10609622 — intervention group
Group type: EXPERIMENTAL
Intervention: HFA albuterol
Number of subjects: 0
Study 10609622 — intervention group
Group type: EXPERIMENTAL
Intervention: CFC albuterol
Number of subjects: 0
Study 10609622 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8953501 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM phosphate, pH 7
Number of subjects: 0
Study 8953501 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mM phosphate, pH 6
Number of subjects: 0
Study 8953501 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mM phosphate, pH 6
Number of subjects: 0
Study 8953501 — intervention group
Group type: EXPERIMENTAL
Intervention: hIGF‐I
Number of subjects: 0
Study 8953501 — intervention group
Group type: COMPARATOR
Intervention: Isotonic saline solution
Number of subjects: 0
Study 1844327 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiload IUD
Number of subjects: 236
Study 1844327 — intervention group
Group type: EXPERIMENTAL
Intervention: Gravigard IUD
Number of subjects: 236
Study 1844327 — intervention group
Group type: COMPARATOR
Intervention: Short IUD-types
Number of subjects: 236
Study 1844327 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer IUDs
Number of subjects: 236
Study 1844327 — intervention group
Group type: COMPARATOR
Intervention: Total uterine cavity length < 7 cm
Number of subjects: 236
Study 1844327 — intervention group
Group type: COMPARATOR
Intervention: IUD insertion in nulligravidae
Number of subjects: 236
Study 1844327 — intervention group
Group type: COMPARATOR
Intervention: Length of uterine cavity vs length of IUD
Number of subjects: 236
Study 7104637 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotic group
Number of subjects: 111
Study 7104637 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 111
Study 7104637 — intervention group
Group type: EXPERIMENTAL
Intervention: Exploration of the common bile duct
Number of subjects: 111
Study 7104637 — intervention group
Group type: EXPERIMENTAL
Intervention: Cholecystectomy alone
Number of subjects: 111
Study 7104637 — intervention group
Group type: EXPERIMENTAL
Intervention: Microscopy of bile
Number of subjects: 111
Study 31030005 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 56
Study 29544501 — intervention group
Group type: COMPARATOR
Intervention: Direct Control (DC)
Number of subjects: 2
Study 29544501 — intervention group
Group type: EXPERIMENTAL
Intervention: EMG Pattern Recognition (PR)
Number of subjects: 2
Study 27776494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-warm moxibustion group (moxa stick 3-5 cm away from acupuncture points, skin temperature 43±1 °C)
Number of subjects: 104
Study 27776494 — intervention group
Group type: COMPARATOR
Intervention: Placebo moxibustion group (moxa stick 8-10 cm away from acupuncture points, skin temperature 37±1 °C)
Number of subjects: 104
Study 27776494 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild-warm moxibustion group
Number of subjects: 104
Study 27776494 — intervention group
Group type: COMPARATOR
Intervention: Placebo moxibustion group
Number of subjects: 104
Study 24789677 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal transcranial direct current stimulation
Number of subjects: 10
Study 24789677 — intervention group
Group type: COMPARATOR
Intervention: Sham direct current stimulation
Number of subjects: 10
Study 22015462 — intervention group
Group type: EXPERIMENTAL
Intervention: Optibond FL
Number of subjects: 12
Study 22015462 — intervention group
Group type: EXPERIMENTAL
Intervention: G Bond
Number of subjects: 12
Study 22015462 — intervention group
Group type: EXPERIMENTAL
Intervention: Other adhesive systems (etch and rinse and self-etch)
Number of subjects: 12
Study 19527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-to-vigorous physical activity (MVPA)
Number of subjects: 1648
Study 19527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Bouts of MVPA
Number of subjects: 1648
Study 19527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Demographic characteristics
Number of subjects: 1648
Study 19527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity by day
Number of subjects: 1648
Study 19527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity by time of day
Number of subjects: 1648
Study 19527591 — intervention group
Group type: EXPERIMENTAL
Intervention: Physical activity duration
Number of subjects: 1648
Study 18782843 — intervention group
Group type: EXPERIMENTAL
Intervention: Bear Brand coffee creamer
Number of subjects: 1124
Study 16045370 — intervention group
Group type: EXPERIMENTAL
Intervention: Medication adherence assessment
Number of subjects: 181
Study 16045370 — intervention group
Group type: EXPERIMENTAL
Intervention: Specific medication-taking behaviors
Number of subjects: 181
Study 16045370 — intervention group
Group type: EXPERIMENTAL
Intervention: Knowledge of blood glucose goals
Number of subjects: 181
Study 16045370 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood pressure and cholesterol medication adherence
Number of subjects: 181
Study 12390568 — intervention group
Group type: EXPERIMENTAL
Intervention: Polydioxanon (PDS) membrane
Number of subjects: 62
Study 12390568 — intervention group
Group type: COMPARATOR
Intervention: Polylactic acid (PLA) matrix barrier
Number of subjects: 62
Study 10206134 — intervention group
Group type: EXPERIMENTAL
Intervention: Acellular pertussis, diphtheria, tetanus vaccine combined with Haemophilus influenzae type b (Hib) vaccine (PRP‐T)
Number of subjects: 262
Study 10206134 — intervention group
Group type: COMPARATOR
Intervention: Whole-cell pertussis, diphtheria, tetanus/PRP‐T vaccine (historical control)
Number of subjects: 262
Study 7772422 — intervention group
Group type: EXPERIMENTAL
Intervention: Droperidol 20 micrograms kg‐1 i.v. at induction of anaesthesia
Number of subjects: 270
Study 2347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Veadent (0.03% sanguinarine and 0.2% zinc chloride)
Number of subjects: 12
Study 2347947 — intervention group
Group type: EXPERIMENTAL
Intervention: Hibident (0.2% chlorhexidine digluconate)
Number of subjects: 12
Study 2347947 — intervention group
Group type: COMPARATOR
Intervention: Vehicle solution (control rinse)
Number of subjects: 12
Study 498714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 25 mg
Number of subjects: 13
Study 498714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 100 mg
Number of subjects: 13
Study 498714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine 150 mg
Number of subjects: 13
Study 498714 — intervention group
Group type: EXPERIMENTAL
Intervention: Amantadine (all doses)
Number of subjects: 13
Study 30280368 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of peony (TGP) 600 mg, tid for 24 weeks
Number of subjects: 320
Study 30280368 — intervention group
Group type: EXPERIMENTAL
Intervention: Total glucosides of peony (TGP)
Number of subjects: 320
Study 30280368 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 320
Study 29474558 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceritinib 750 mg/day
Number of subjects: 29
Study 29474558 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (intravenous pemetrexed 500 mg/m2 or docetaxel 75 mg/m2)
Number of subjects: 29
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Average systolic BP ≥160 mm Hg
Number of subjects: 1767
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Average systolic BP of 120 to 139 mm Hg
Number of subjects: 1767
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Average systolic BP <120 mm Hg
Number of subjects: 1767
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic BP ≥90 mm Hg
Number of subjects: 1767
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulse pressure <50 mm Hg
Number of subjects: 1767
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: Systolic BP ≥160 mm Hg
Number of subjects: 1767
Study 27486164 — intervention group
Group type: EXPERIMENTAL
Intervention: BP of 120 to 129 mm Hg
Number of subjects: 1767
Study 25248448 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Observation (S-O)
Number of subjects: 39
Study 25248448 — intervention group
Group type: EXPERIMENTAL
Intervention: Other-Observation (O-O)
Number of subjects: 39
Study 25248448 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 39
Study 22321061 — intervention group
Group type: EXPERIMENTAL
Intervention: Exemestane
Number of subjects: 131
Study 22321061 — intervention group
Group type: COMPARATOR
Intervention: Tamoxifen
Number of subjects: 131
Study 19834744 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based walking exercise intervention for 8 weeks
Number of subjects: 71
Study 19834744 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 71
Study 17559747 — intervention group
Group type: EXPERIMENTAL
Intervention: DPP-4 inhibitors (sitagliptin, vildagliptin)
Number of subjects: 0
Study 17559747 — intervention group
Group type: COMPARATOR
Intervention: Sulphonylureas, glitazones, basal insulin
Number of subjects: 0
Study 15951453 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 12047016 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation program (3 months)
Number of subjects: 42
Study 12047016 — intervention group
Group type: COMPARATOR
Intervention: Leisure group (control condition)
Number of subjects: 42
Study 12973416 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat
Number of subjects: 0
Study 12973416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7737103 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (150 mg)
Number of subjects: 18
Study 7737103 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study 7737103 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine (200 mg)
Number of subjects: 18
Study 2292696 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (up to 3g daily for eight weeks)
Number of subjects: 33
Study 2292696 — intervention group
Group type: EXPERIMENTAL
Intervention: Vigabatrin (during double-blind phase)
Number of subjects: 33
Study 2292696 — intervention group
Group type: COMPARATOR
Intervention: Placebo (during double-blind phase)
Number of subjects: 33
Study 7264612 — intervention group
Group type: EXPERIMENTAL
Intervention: HANAflu with 1 microgram (5%) whole virus added
Number of subjects: 0
Study 7264612 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial vaccine
Number of subjects: 0
Study 7264612 — intervention group
Group type: EXPERIMENTAL
Intervention: HANAflu alone
Number of subjects: 0
Study 7264612 — intervention group
Group type: EXPERIMENTAL
Intervention: HANAflu + 0.2 microgram (1%) whole virus
Number of subjects: 0
Study 31682327 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience programming (four-session program including goal-building, mindfulness, and resilience skills)
Number of subjects: 252
Study 31682327 — intervention group
Group type: EXPERIMENTAL
Intervention: Resilience programming
Number of subjects: 252
Study 31682327 — intervention group
Group type: COMPARATOR
Intervention: Orientation-as-usual (control group)
Number of subjects: 252
Study 29593782 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral tDCS (cathode over C4, anode over C3)
Number of subjects: 0
Study 29593782 — intervention group
Group type: COMPARATOR
Intervention: Sham stimulation
Number of subjects: 0
Study 27776843 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT group (docetaxel 50 mg/m2, oxaliplatin 85 mg/m2, leucovorin 200 mg/m2, fluorouracil 2600 mg/m2)
Number of subjects: 300
Study 27776843 — intervention group
Group type: COMPARATOR
Intervention: ECF/ECX group (epirubicin 50 mg/m2, cisplatin 60 mg/m2, fluorouracil 200 mg/m2 or capecitabine 1250 mg/m2)
Number of subjects: 300
Study 27776843 — intervention group
Group type: EXPERIMENTAL
Intervention: FLOT group
Number of subjects: 300
Study 27776843 — intervention group
Group type: COMPARATOR
Intervention: ECF/ECX group
Number of subjects: 300
Study 24836086 — intervention group
Group type: EXPERIMENTAL
Intervention: Reboxetine
Number of subjects: 0
Study 24836086 — intervention group
Group type: COMPARATOR
Intervention: Citalopram
Number of subjects: 0
Study 22781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated oscillometric device (Omron M7)
Number of subjects: 1729
Study 22781634 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment of automated oscillometric measurements
Number of subjects: 1729
Study 20820146 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure Controlled Ventilation (PCV)
Number of subjects: 40
Study 20820146 — intervention group
Group type: COMPARATOR
Intervention: Sustained Inflation (SI)
Number of subjects: 40
Study 18269367 — intervention group
Group type: EXPERIMENTAL
Intervention: Happy Ending intervention (internet- and cell-phone-based), lasting 54 weeks with over 400 contacts via e-mail, web-pages, IVR, and SMS
Number of subjects: 396
Study 18269367 — intervention group
Group type: COMPARATOR
Intervention: Self-help booklet (control group)
Number of subjects: 396
Study 16466178 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiaozhi Jiangtang Tablet (TZJT) plus asprin
Number of subjects: 60
Study 16466178 — intervention group
Group type: COMPARATOR
Intervention: Asprin alone
Number of subjects: 60
Study 12834653 — intervention group
Group type: EXPERIMENTAL
Intervention: Spit tobacco (ST) intervention
Number of subjects: 1084
Study 12834653 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 1084
Study 10945385 — intervention group
Group type: EXPERIMENTAL
Intervention: Suprasternal Doppler (SST)
Number of subjects: 65
Study 10945385 — intervention group
Group type: COMPARATOR
Intervention: Thermodilution (TD)
Number of subjects: 65
Study 8997686 — intervention group
Group type: EXPERIMENTAL
Intervention: Relaxation response training
Number of subjects: 33
Study 8997686 — intervention group
Group type: COMPARATOR
Intervention: Reading (attention-control group)
Number of subjects: 33
Study 8997686 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 33
Study 1464681 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional internal measurements across the osteotomy lines (15 subjects)
Number of subjects: 45
Study 1464681 — intervention group
Group type: COMPARATOR
Intervention: Measurements between the incisor teeth and an external reference point (bone screw at nasion) (30 subjects total, 15 subjects in each group)
Number of subjects: 45
Study 6509452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy alone
Number of subjects: 95
Study 6509452 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy and radiotherapy
Number of subjects: 95
Study 6509452 — intervention group
Group type: COMPARATOR
Intervention: Control group (patients without secondary leukemia)
Number of subjects: 95
Study 6509452 — intervention group
Group type: EXPERIMENTAL
Intervention: All patients with secondary leukemia
Number of subjects: 95
Study 6509452 — intervention group
Group type: EXPERIMENTAL
Intervention: Time to first sign of preleukemia
Number of subjects: 95
Study 31524774 — intervention group
Group type: EXPERIMENTAL
Intervention: Melatonin 3 mg tablets plus indomethacin suppository 100 mg
Number of subjects: 411
Study 31524774 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus indomethacin suppository 100 mg
Number of subjects: 411
Study 30306951 — intervention group
Group type: EXPERIMENTAL
Intervention: Basic platform
Number of subjects: 809
Study 30306951 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced platform
Number of subjects: 809
Study 30306951 — intervention group
Group type: COMPARATOR
Intervention: Minimal intervention control group
Number of subjects: 809
Study 25640652 — intervention group
Group type: EXPERIMENTAL
Intervention: Prayer for romantic partner (self-guided, lasted 3 minutes)
Number of subjects: 151
Study 25640652 — intervention group
Group type: COMPARATOR
Intervention: Control condition (describing romantic partner's physical attributes)
Number of subjects: 151
Study 24117862 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous belimumab 200 mg
Number of subjects: 16
Study 24117862 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous belimumab 200 mg
Number of subjects: 16
Study 22084490 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV-full group (n = 20)
Number of subjects: 55
Study 22084490 — intervention group
Group type: EXPERIMENTAL
Intervention: WBV-light group (n = 18)
Number of subjects: 55
Study 22084490 — intervention group
Group type: COMPARATOR
Intervention: Control group (n = 17)
Number of subjects: 55
Study 21179725 — intervention group
Group type: EXPERIMENTAL
Intervention: Xuefu Zhuyu Decoction (XFZYD)
Number of subjects: 120
Study 21179725 — intervention group
Group type: COMPARATOR
Intervention: Conventional treatment (Control)
Number of subjects: 120
Study 18046186 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity resistance training program (3 sets of 12 repetitions at 54.9 +/- 2.4% 1RM, 3 times per week for 12 months)
Number of subjects: 42
Study 18046186 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 42
Study 16127757 — intervention group
Group type: EXPERIMENTAL
Intervention: HCPT d1 and d14 through TAE and portal venous embolization (test group)
Number of subjects: 296
Study 16127757 — intervention group
Group type: COMPARATOR
Intervention: Anticancer drugs without HCPT (control I)
Number of subjects: 296
Study 16127757 — intervention group
Group type: COMPARATOR
Intervention: HCPT as a major component in anticancer drugs once (control II)
Number of subjects: 296
Study 12403023 — intervention group
Group type: EXPERIMENTAL
Intervention: Nelfinavir/Zalcitabine/Zidovudine combination
Number of subjects: 40
Study 10457880 — intervention group
Group type: EXPERIMENTAL
Intervention: Tramadol suppositories 100 mg 6 hourly (qds)
Number of subjects: 40
Study 10457880 — intervention group
Group type: COMPARATOR
Intervention: Acetaminophen/codeine suppositories 1000/20 mg qds
Number of subjects: 40
Study 7847300 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous infusion of famotidine (20 mg bolus followed by 1.67 mg/h infusion)
Number of subjects: 40
Study 7847300 — intervention group
Group type: COMPARATOR
Intervention: Intermittent administration of famotidine (20 mg every 12 h)
Number of subjects: 40
Study 7847300 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 40
Study 2192839 — intervention group
Group type: EXPERIMENTAL
Intervention: Zinc gluconate lozenges (4.5 mg zinc)
Number of subjects: 463
Study 2192839 — intervention group
Group type: COMPARATOR
Intervention: Placebo lozenges
Number of subjects: 463